Tu-Ying Yong (Tuying Yong)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Venues

Cancer gene therapy

Nature communications

Advanced materials (Deerfield Beach, Fla.)

Signal transduction and targeted therapy

Huazhong University of Science and Technology (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Huazhong University of Science and Technology

China

PHD :: College of Life Science and Technology

Huazhong University of Science and Technology

China

BSC :: College of Life Science and Technology

Publications

Gan-Xun Li, Rui-Zhi Chang, Tong-Tong Liu, Guan-Nan Jin, Kan Lu, Tu-Ying Yong, Zifu Li, Ji-Hong Liu, Bixiang Zhang, Wan-Guang Zhang, Ze-Yang Ding
GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers. Cancer gene therapy 31 (4) (2024)
Gan-Xun Li, Rui-Zhi Chang, Tong-Tong Liu, Guan-Nan Jin, Kan Lu, Tu-Ying Yong, Zifu Li, Ji-Hong Liu, Bixiang Zhang, Wan-Guang Zhang, Ze-Yang Ding
GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers. Cancer gene therapy 31 (4) (2024)
Gan-Xun Li, Rui-Zhi Chang, Tong-Tong Liu, Guan-Nan Jin, Kan Lu, Tu-Ying Yong, Zifu Li, Ji-Hong Liu, Bixiang Zhang, Wan-Guang Zhang, Ze-Yang Ding
GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers. Cancer gene therapy (2024)
Gan-Xun Li, Rui-Zhi Chang, Tong-Tong Liu, Guan-Nan Jin, Kan Lu, Tu-Ying Yong, Zifu Li, Ji-Hong Liu, Bixiang Zhang, Wan-Guang Zhang, Ze-Yang Ding
GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers. Cancer gene therapy 31 (4) (2024)
Nana Bie, Tu-Ying Yong, Zhaohan Wei, Qingle Liang, Xiaoqiong Zhang, Shiyu Li, Xin Li, Jianye Li, Lu Gan, Xiangliang Yang
Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy. Signal transduction and targeted therapy 8 (1) (2023)
Xiaoqiong Zhang, Zhaohan Wei, Tu-Ying Yong, Shiyu Li, Nana Bie, Jianye Li, Xin Li, Haojie Liu, Hang Xu, Yuchen Yan, Bixiang Zhang, Xiao-Ping Chen, Xiangliang Yang, Lu Gan
Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8 + T cells to boost anti-PD-1 therapy. Nature communications 14 (1) (2023)
Tu-Ying Yong, Zhaohan Wei, Lu Gan, Xiangliang Yang
Extracellular-Vesicle-Based Drug Delivery Systems for Enhanced Antitumor Therapies through Modulating the Cancer-Immunity Cycle. Advanced materials (Deerfield Beach, Fla.) (2022)
Xin Li, Tu-Ying Yong, Zhaohan Wei, Nana Bie, Xiaoqiong Zhang, Guiting Zhan, Jianye Li, Jiaqi Qin, Jingjing Yu, Bixiang Zhang, Lu Gan, Xiangliang Yang
Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts. Nature communications 13 (1) (2022)
Tu-Ying Yong, Xiaoqiong Zhang, Nana Bie, Hongbo Zhang, Xuting Zhang, Fuying Li, Abdul Hakeem, Jun Hu, Lu Gan, Hélder Almeida Santos, Xiangliang Yang
Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nature communications 10 (1) (2019)

Tu-Ying Yong.css-eqlu8i{font-size:small;padding-left:4px;} (Tuying Yong)

Publication Activity (10 Years)

Top Topics

Top Venues

Tu-Ying Yong (Tuying Yong)